A qualitative hybrid III implementation study to identify and evaluate strategies for successful implementation of the cabotegravir + rilpivirine long-acting injectable regimen in the US

About this Study

This study will test the efficacy of two long acting HIV antiretroviral medications administered as injections every month. This study will help us to understand the barriers and facilitators using this method of treatment and what training and support clinics need to deliver this injectable medication to patients. 

Sponsor Protocol ID:209493
IRB Number:2019-0161
Closed for Enrollment
Interventional
Phase 3
August 26, 2019
Eligibility Criteria
18 years old
100 years old
Both Male and Female
No
No
No

Inclusion CriteriaA participant will be eligible for inclusion in this study only if all of the following criteria apply: 

 Be able to understand and comply with protocol requirements, instructions, and restrictions; 

 Understand the long-term commitment to the study and be likely to complete the study as planned; 


Exclusion Criteria
1. Women who are pregnant, breastfeeding, or plan to become pregnant or breastfeed during the study. 

2. Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant’s ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant. 

3. Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. 

4. Participants who, in the investigator's judgment, pose a significant suicide risk. Participant’s recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk 

5. The participant has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions 

6. History of liver cirrhosis with or without hepatitis viral co-infection.
 
7. Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication  



Categories Click category to view its trials.
Infectious Diseases
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Courtney Sims Gomillia
Phone Number: 601-815-4259
Email: cegomillia@umc.edu
Principal Investigator:Leandro Mena
How to participate in our Clinical Trials